FDA Panel will Scrutinize Non-MRI Breast Implant Rupture Rates
Apr 7, 2005 - 3:11:00 PM
|
|
|
FDA points out that Inameds model uses the following assumptions: that the silent rupture rate in the non-MRI cohort can be predicted from the MRI cohort; that averaging the increase in rupture rate at yearly intervals is appropriate; that the rate at which rupture occurs over time is constant; and that averaging the augmentation, reconstruction and revision rupture rates is appropriate.
|
By FDA advisory committe,
[RxPG] FDA will solicit feedback from its General & Plastic Surgery Devices Panel on whether Inamed and Mentors non-MRI breast implant cohort groups accurately reflect true rupture rates.
The advisory panel will convene April 11-13 to review both firms PMAs for silicone-filled breast implants.
Since the majority of ruptures for silicone breast implants are silent and therefore unlikely to be detected without magnetic resonance imaging FDAs draft questions ask whether the two companies adequately characterized the rupture rate.
Results from the firms respective studies showed disparate reported rates between the MRI and non-MRI groups.
Approximately one-third of the 1,000 patients enrolled in Mentors pivotal study underwent serial MRI at one and two years following implantation. Rupture rates through three years were 0.5% for augmentation, 0.8% for reconstruction and 4.8% for revision, according to FDAs draft panel questions for Mentor. However, no ruptures were reported in the non-MRI cohort.
To address FDAs concerns with rupture rates over the anticipated device lifetime, Mentor used a case series of augmentation patients with subglandular implants who did not have capsular contracture or any recurrent surgical procedures, and who received a single MRI to screen for ruptures.
An estimated one-third of the 940 patients in Inameds core study also received a serial MRI at one and three years following implantation. Total rupture rates at four years were 3.4% for augmentation, 20.5% for reconstruction and 10.9% for revision, according to FDAs draft panel questions for Inamed.
In Inameds non-MRI cohort, total rupture rates through four years were 1.1% for augmentation, 4.9% for reconstruction and 1.7% for revision.
Inamed modeled a hypothetical curve extrapolating the rupture rate seen in the core study to estimate a 14% by-implant, 10-year rupture rate for the augmentation, reconstruction and revision groups.
FDA points out that Inameds model uses the following assumptions: that the silent rupture rate in the non-MRI cohort can be predicted from the MRI cohort; that averaging the increase in rupture rate at yearly intervals is appropriate; that the rate at which rupture occurs over time is constant; and that averaging the augmentation, reconstruction and revision rupture rates is appropriate.
There are other models which could be selected, which lead to higher rates of rupture, FDA states. In a presentation summary, the agency considers that ruptures could increase linearly with time, or on a quadratic basis.
When Inamed went before the panel in October 2003, panelists similarly expressed concerns with silent rupture. Although the panel issued a positive recommendation for approval, FDA ultimately opted against approving the silicone implants.
In addition to rupture concerns, FDAs draft questions address Mentor and Inameds proposed postmarket study plans. The firms both propose to provide physician follow-up for patients in their core studies, with MRIs occurring every two years through the 10-year mark.
Mentor plans to terminate follow-up for patients whose implants are removed during the 10-year period and who do not receive a replacement from the study, while Inamed will continue to follow them via telephone. Neither firm plans to collect data on children of women who have implants.
While safety and efficacy data will continue to be collected, Inamed does not intend to complete the quality-of-life questionnaire at the six, eight and 10-year marks.
In addition, Mentor plans to use three existing breast implant registries, involving physicians who voluntarily collect local complication data when patients return for a visit.
Although Inamed proposes to tap the Danish Registry or third-party organizations such as the National Institutes of Health to collect data addressing outstanding concerns with the 2003 panel review, the firm did not describe any specific plans for using these sources of information, FDA said.
Inamed also plans to link its voluntary registry, which gathers baseline and demographic data but no postoperative information, to its rupture warranty program.
Although FDAs questions regarding Inamed and Mentors applications are similar, the agency is soliciting feedback on whether Mentors implants are efficacious. Inamed successfully demonstrated efficacy at its 2003 panel review.
Advertise in this space for $10 per month.
Contact us today.
|
 |
|
Subscribe to Breast Cancer Newsletter
|
|
|
|
Additional information about the news article
|
This meeting will be held April 11, 2005 at the Hilton, Gaithersburg, Md. beginning at 8 a.m.
|
|
Feedback
|
For any corrections of factual information, to contact the editors or to send
any medical news or health news press releases, use
feedback form
|
Top of Page
|
